Pharma, FDA Got A Bum Rap On Post-Market Studies, Booz Allen Report Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly 20 percent of post-marketing studies tagged in the agency's database as open had actually been fulfilled or released, according to the backlog review.
You may also be interested in...
FDA Database Clean-Up Causes Jump In "Concluded" Postmarketing Studies
A more than two-fold increase in the number of concluded study requirements and commitments in fiscal 2009 appears largely attributable to a consulting firm's clean-up of FDA's postmarketing obligations database.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.